The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
HOME > REGULATORY
REGULATORY
- MHLW Announces Results of Reexamination for Iressa, Remicade as Category I
December 5, 2011
- PAFSC 2nd Committee Recommends Designation of Thalidomide, Imatinib Mesylate as Orphan Drugs
December 5, 2011
- Decision on Price Freeze for Medically Essential Drugs to Be Postponed
December 5, 2011
- Expert Subcommittee Approves 60% Pricing Rule for Some New Generics Only
December 5, 2011
- NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 5, 2011
- NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 3, 2011
- Two New Drugs Including Ranmark from Daiichi Sankyo Recommended at PAFSC's 2nd Committee
December 2, 2011
- SS Council Committees Approve Basic Plan on FY2012 Medical Fee Revision
December 2, 2011
- Average Discrepancy Rate Remains at Approximately 8.4%: MHLW Flash Report
December 2, 2011
- Discussion Items for Upcoming Reform of NHI Drug Pricing System (Expert Subcommittee on NHI Drug Pricing Affairs, Dec. 2)
December 2, 2011
- CSIMC Approves Outline of Plan to Promote Generic Drug Use
December 1, 2011
- MHLW Announces Revision of Precautions for Anastrozole, Temozolomide
December 1, 2011
- CSIMC Expert Member Yoshimura Says Conditions Must Improve to Promote Generics
November 30, 2011
- Gov’t to Decide on Extension of Urgent Vaccination Project “as Soon as Possible”
November 30, 2011
- MLHW Announces Extension of Reexamination Period for Lonasen
November 29, 2011
- JAN Determined for 8 Drug Candidate Compounds
November 29, 2011
- Record 101 Generics from 30 Companies Listed for Aricept
November 29, 2011
- MHLW Says Sept Drug Price Settlement Rate Dips to 78.1%, Falling Below 2009 Level
November 28, 2011
- MHLW Issues Notification on Modifications of Approval for Iressa
November 28, 2011
- CSIMC to Discuss Additional Price Cuts for Long-Listed Drugs
November 28, 2011
ページ
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…